Product Description
DM005 is a bispecific antibody-drug conjugate (ADC) designed to treat solid tumors by targeting both MET and EGFR receptors. The bispecific antibody was assembled using common light chain antibodies produced by RenLite, a fully human antibody mouse originates from Biocytogen. Its monoclonal antibody structure facilitates easy purification and drug conjugation. (Sourced from: https://en.domabio.com/pipeline/10.html)
Mechanisms of Action: C-Met Inhibitor,EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Doma Biopharmaceuticalï¼Suzhouï¼Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|